Literature DB >> 25364037

Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.

Shannon Gwin Mitchell1, Jan Gryczynski1, Sharon M Kelly1, Kevin E O'Grady2, Jerome H Jaffe3, Yngvild K Olsen4, Robert P Schwartz1.   

Abstract

This secondary analysis compared outcomes of African-American adults newly-admitted to buprenorphine treatment who were on parole and probation to patients who were not under criminal justice supervision. Buprenorphine patients (N=300) were randomly assigned to receive either Intensive Outpatient Treatment (IOP) or Standard Outpatient Treatment (OP) treatment and were assessed at baseline, 3- and 6-months. There were no differences between groups in treatment retention. Among probationers/parolees, IOP was associated with lower 3-month treatment retention compared to OP, but among participants not on probation/parole the relationship was reversed (p=.004). Both conditions showed significant declines in heroin and cocaine use, illegal activity, and in meeting DSM-IV criteria for opioid and cocaine dependence. Probationers/parolees reported lower frequency of illegal activities at 3-months compared to non-probationers/parolees (p=.007). Buprenorphine treatment should be made more widely available to individuals on parole/probation as they respond as well to treatment as patients not supervised by the criminal justice system.

Entities:  

Keywords:  African Americans; Buprenorphine treatment; Criminal Justice; Drug Abuse Treatment; Parole and Probation

Year:  2014        PMID: 25364037      PMCID: PMC4214068          DOI: 10.1177/0022042613491106

Source DB:  PubMed          Journal:  J Drug Issues        ISSN: 0022-0426


  48 in total

1.  Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.

Authors:  L Amass; J B Kamien; S K Mikulich
Journal:  Drug Alcohol Depend       Date:  2000-02-01       Impact factor: 4.492

2.  Compulsory supervision and methadone maintenance.

Authors:  D P Desmond; J F Maddux
Journal:  J Subst Abuse Treat       Date:  1996 Jan-Feb

3.  Naltrexone pharmacotherapy for opioid dependent federal probationers.

Authors:  J W Cornish; D Metzger; G E Woody; D Wilson; A T McLellan; B Vandergrift; C P O'Brien
Journal:  J Subst Abuse Treat       Date:  1997 Nov-Dec

4.  A randomized controlled trial of interim methadone maintenance.

Authors:  Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes
Journal:  Arch Gen Psychiatry       Date:  2006-01

5.  Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system.

Authors:  Karen L Cropsey; Peter S Lane; Galen J Hale; Dorothy O Jackson; C Brendan Clark; Karen S Ingersoll; M Aminul Islam; Maxine L Stitzer
Journal:  Drug Alcohol Depend       Date:  2011-07-23       Impact factor: 4.492

6.  Interim methadone treatment: impact on arrests.

Authors:  Robert P Schwartz; Jerome H Jaffe; Kevin E O'Grady; Timothy W Kinlock; Michael S Gordon; Sharon M Kelly; Monique E Wilson; Ashraf Ahmed
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

7.  A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.

Authors:  V P DOLE; M NYSWANDER
Journal:  JAMA       Date:  1965-08-23       Impact factor: 56.272

8.  Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.

Authors:  Sandra Ann Springer; Shu Chen; Frederick L Altice
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

Review 9.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 10.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08
View more
  6 in total

1.  Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices.

Authors:  Shannon Gwin Mitchell; Jennifer Willet; Laura B Monico; Amy James; Danielle S Rudes; Jill Viglione; Robert P Schwartz; Michael S Gordon; Peter D Friedmann
Journal:  Subst Abus       Date:  2016       Impact factor: 3.716

2.  Pharmacotherapy for opioid addiction in community corrections.

Authors:  Robert P Schwartz; Mary M Mitchell; Kevin E O'Grady; Sharon M Kelly; Jan Gryczynski; Shannon Gwin Mitchell; Michael S Gordon; Jerome H Jaffe
Journal:  Int Rev Psychiatry       Date:  2018-12-06

3.  Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.

Authors:  Daniel P Riggins; Chinazo O Cunningham; Yuming Ning; Aaron D Fox
Journal:  Subst Abus       Date:  2016-08-11       Impact factor: 3.716

4.  HIV-Risk Behavior Among Adults with Opioid Use Disorder During 12 Months Following Pre-trial Detention: Results from a Randomized Trial of Methadone Treatment.

Authors:  M M Mitchell; S M Kelly; K E O'Grady; J H Jaffe; S G Mitchell; R P Schwartz
Journal:  AIDS Behav       Date:  2020-11-16

5.  Interventions for female drug-using offenders.

Authors:  Amanda E Perry; Marrissa Martyn-St James; Lucy Burns; Catherine Hewitt; Julie M Glanville; Anne Aboaja; Pratish Thakkar; Keshava Murthy Santosh Kumar; Caroline Pearson; Kath Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-12-13

Review 6.  Interventions for drug-using offenders with co-occurring mental health problems.

Authors:  Amanda E Perry; Marrissa Martyn-St James; Lucy Burns; Catherine Hewitt; Julie M Glanville; Anne Aboaja; Pratish Thakkar; Keshava Murthy Santosh Kumar; Caroline Pearson; Kath Wright; Shilpi Swami
Journal:  Cochrane Database Syst Rev       Date:  2019-10-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.